BIOGEN (BIIB)
We think the company has a above average capital gains return. The comèany has taken a lot of debt, and we belive that that debt will be used soon to make an acquisition. Potential target is Shire Pharma.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。